Immunomodulatory Therapy in Uveitis

  • Stephan R. Thurau
  • Gerhild Wildner
Part of the Essentials in Ophthalmology book series (ESSENTIALS)


Mycophenolate Mofetil Anterior Uveitis Oral Tolerance Immunomodulatory Therapy Posterior Uveitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Akpek EK, Baltatzis S, Yang J, et al. (2001) Long-term immunosuppressive treatment of serpiginous choroiditis. Ocul Immunol Inflamm 9:153–167CrossRefPubMedGoogle Scholar
  2. 2.
    Akpek EK, Ilhan Sarac O (2003) New treatments for serpiginous choroiditis. Curr Opin Ophthalmol 14:128–131CrossRefPubMedGoogle Scholar
  3. 3.
    Akpek EK, Jabs DA, Tessler HH, et al. (2002) Successful treatment of serpiginous choroiditis with alkylating agents. Ophthalmology 109:1506–1513CrossRefPubMedGoogle Scholar
  4. 4.
    Arnett HA, Mason J, Marino M, et al. (2001) TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 4:1116–1122CrossRefPubMedGoogle Scholar
  5. 5.
    Baltatzis S, Tufail F, Yu EN, et al. (2003) Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology 110:1061–1065CrossRefPubMedGoogle Scholar
  6. 6.
    BenEzra D, Cohen E, Chajek T, et al. (1988) Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc 20:136–143Google Scholar
  7. 7.
    Benitez Del Castillo JM, Garcia Sanchez J, Iradier T, et al. (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye 14:340–343PubMedGoogle Scholar
  8. 8.
    Bom S, Zamiri P, Lightman S (2001) Use of methotrexate in the management of sight-threatening uveitis. Ocul Immunol Inflamm 9:35–40CrossRefPubMedGoogle Scholar
  9. 9.
    Brock N (1989) Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture. Cancer Res 49:1–7PubMedGoogle Scholar
  10. 10.
    Cannon J, Linke CA, Cos LR (1991) Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention. Urology 38:413–416PubMedGoogle Scholar
  11. 11.
    Caspi RR (2002) Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int Rev Immunol 21:197–208PubMedGoogle Scholar
  12. 12.
    Christmas NJ, Oh KT, Oh DM, et al. (2002) Long-term follow-up of patients with serpiginous choroiditis. Retina 22:550–556PubMedGoogle Scholar
  13. 13.
    Clements PJ, Davis J (1986) Cytotoxic drugs: their clinical application to the rheumatic diseases. Semin Arthritis Rheum 15:231–254CrossRefPubMedGoogle Scholar
  14. 14.
    Deeg CA, Thurau SR, Gerhards H, et al. (2002) Uveitis in horses induced by interphotoreceptor retinoid-binding protein is similar to the spontaneous disease. Eur J Immunol 32:2598–2606CrossRefPubMedGoogle Scholar
  15. 15.
    Eigler A, Sinha B, Hartmann G, et al. (1997) Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18:487–492CrossRefPubMedGoogle Scholar
  16. 16.
    El Shabrawi Y, Hermann J (2002) Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109:2342–2346CrossRefPubMedGoogle Scholar
  17. 17.
    Estrach C, Mpofu S, Moots RJ (2002) Behcet's syndrome: response to infliximab after failure of etanercept. Rheumatology (Oxford) 41:1213–1214CrossRefGoogle Scholar
  18. 18.
    Foroozan R, Buono LM, Sergott RC, et al. (2002) Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120:985–987PubMedGoogle Scholar
  19. 19.
    Foster CS, Tufail F, Waheed NK, et al. (2003) Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 121:437–440CrossRefPubMedGoogle Scholar
  20. 20.
    Frassanito MA, Dammacco R, Fusaro T, et al. (2003) Combined cyclosporin-A/prednisone therapy of patients with active uveitis suppresses IFN-gamma production and the function of dendritic cells. Clin Exp Immunol 133:233–239CrossRefPubMedGoogle Scholar
  21. 21.
    Fries W, Giofre MR, Catanoso M, et al. (2002) Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. Am J Gastroenterol 97:499–500PubMedGoogle Scholar
  22. 22.
    Gion N, Stavrou P, Foster CS (2000) Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol 129:764–768CrossRefPubMedGoogle Scholar
  23. 23.
    Goldstein DA, Fontanilla FA, Kaul S, et al. (2002) Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammation. Ophthalmology 109:370–377CrossRefPubMedGoogle Scholar
  24. 24.
    Greiner K, Murphy CC, Willermain F, et al. (2004) Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest Ophthalmol Vis Sci 45:170–176CrossRefPubMedGoogle Scholar
  25. 25.
    Greiner K, Varikkara M, Santiago C, et al. (2002) Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis. Ophthalmologe 99:691–694CrossRefPubMedGoogle Scholar
  26. 26.
    Guex Crosier Y, Raber J, Chan CC, et al. (1997) Humanized antibodies against the alpha-chain of the IL-2 receptor and against the beta-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J Immunol 158:452–458PubMedGoogle Scholar
  27. 27.
    Hamuryudan V, Mat C, Saip S, et al. (1998) Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 128:443–450PubMedGoogle Scholar
  28. 28.
    Hanke JH, Nichols LN, Coon ME (1992) FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. Lymphokine Cytokine Res 11:221–231Google Scholar
  29. 29.
    Hudde T, Heinz C, Neudorf U, et al. (2002) Tubulointerstitial nephritis and uveitis (TINU syndrome) — comorbidity and complications in four patients. Klin Monatsbl Augenheilkd 219:528–532CrossRefPubMedGoogle Scholar
  30. 30.
    Isnard Bagnis C, Tezenas du Montcel S, Beaufils H, et al. (2002) Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 13:2962–2968PubMedGoogle Scholar
  31. 31.
    Jordan JF, Walter P, Ayertey HD, et al. (2003) Intermediate uveitis in childhood preceding the diagnosis of multiple sclerosis: a 13-year follow-up. Am J Ophthalmol 135:885–886PubMedGoogle Scholar
  32. 32.
    Joseph A, Raj D, Dua HS, et al. (2003) Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 110:1449–1453PubMedGoogle Scholar
  33. 33.
    Kaklamani VG, Kaklamanis PG (2001) Treatment of Behcet's disease — an update. Semin Arthritis Rheum 30:299–312PubMedGoogle Scholar
  34. 34.
    Kaplan Messas A, Barkana Y, Avni I, et al. (2003) Methotrexate as a first-line corticosteroid-sparing therapy in a cohort of uveitis and scleritis. Ocul Immunol Inflamm 11:131–139PubMedGoogle Scholar
  35. 35.
    Kari JA, Shah V, Dillon MJ (2001) Behcet's disease in UK children: clinical features and treatment including thalidomide. Rheumatology (Oxford) 40:933–938CrossRefPubMedGoogle Scholar
  36. 36.
    Kilmartin DJ, Fletcher ZJ, Almeida JA, et al. (2001) CD69 expression on peripheral CD4+ T cells parallels disease activity and is reduced by mycophenolate mofetil therapy in uveitis. Invest Ophthalmol Vis Sci 42:1285–1292PubMedGoogle Scholar
  37. 37.
    Kiss S, Letko E, Qamruddin S, et al. (2003) Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome. Ophthalmology 110:1764–1769CrossRefPubMedGoogle Scholar
  38. 38.
    Klausner JD, Freedman VH, Kaplan G (1996) Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin Immunol Immunopathol 81:219–223CrossRefPubMedGoogle Scholar
  39. 39.
    Kotter I, Zierhut M, Eckstein AK, et al. (2003) Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431CrossRefPubMedGoogle Scholar
  40. 40.
    Kulkarni P (2001) Review: uveitis and immunosuppressive drugs. J Ocul Pharmacol Ther 17:181–187CrossRefPubMedGoogle Scholar
  41. 41.
    Larkin G, Lightman S (1999) Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology 106:370–374PubMedGoogle Scholar
  42. 42.
    Lim WS, Powell RJ, Johnston ID (2002) Tuberculosis and treatment with infliximab. N Engl J Med 346:623–626CrossRefGoogle Scholar
  43. 43.
    Liu J (1993) FK506 and cyclosporin, molecular probes for studying intracellular signal transduction. Immunol Today 14:290–295CrossRefPubMedGoogle Scholar
  44. 44.
    Masli S, Turpie B, Streilein JW (2003) By altering TNFR2:TNFR1 expression, TGFb prevents ACAID-inducing antigen presenting cells from secreting IL-12. Invest Ophthalmol Vis Sci E-Abstract 44:990Google Scholar
  45. 45.
    Michel S-S, Ekong A, Baltatzis S, et al. (2002) Multifocal choroiditis and panuveitis: immunomodulatory therapy. Ophthalmology 109:378–383CrossRefPubMedGoogle Scholar
  46. 46.
    Mikuls TR, Moreland LW (2003) Benefit-risk assessment of infliximab in the treatment of rheumatoid arthritis. Drug Saf 26:23–32PubMedGoogle Scholar
  47. 47.
    Miserocchi E, Baltatzis S, Ekong A, et al. (2002) Efficacy and safety of chlorambucil in intractable noninfectious uveitis: the Massachusetts Eye and Ear Infirmary experience. Ophthalmology 109:137–142CrossRefPubMedGoogle Scholar
  48. 48.
    Mudun BA, Ergen A, Ipcioglu SU, et al. (2001) Short-term chlorambucil for refractory uveitis in Behcet's disease. Ocul Immunol Inflamm 9:219–229CrossRefPubMedGoogle Scholar
  49. 49.
    Munoz Fernandez S, Hidalgo V, Fernandez Melon J, et al.(2003) Sulfasalazine reduces the number of flares of acute anterior uveitis over a one-year period. J Rheumatol 30:1277–1279PubMedGoogle Scholar
  50. 50.
    Nussenblatt RB, Fortin E, Schiffman R, et al. (1999) Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc Natl Acad Sci U S A 96:7462–7466CrossRefPubMedGoogle Scholar
  51. 51.
    Nussenblatt RB, Gery I, Weiner HL, et al. (1997) Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol 123:583–592PubMedGoogle Scholar
  52. 52.
    Nussenblatt RB, Palestine AG, Rook AH, et al. (1983) Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 2:235–238CrossRefPubMedGoogle Scholar
  53. 53.
    Nussenblatt RB, Thompson DJ, Li Z, et al. (2003) Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun 21:283–293CrossRefPubMedGoogle Scholar
  54. 54.
    Nussenblatt RB, Whitcup SM, de Smet MD, et al. (1996) Intraocular inflammatory disease (uveitis) and the use of oral tolerance: a status report. Ann N Y Acad Sci 778:325–337PubMedGoogle Scholar
  55. 55.
    Ozdal PC, Ortac S, Taskintuna I, et al. (2002) Long-term therapy with low dose cyclosporin A in ocular Behcet's disease. Doc Ophthalmol 105:301–312CrossRefPubMedGoogle Scholar
  56. 56.
    Patil CR, Bhise SB (2003) Re-emergence of thalidomide. Ind J Pharmacol 35:204–212Google Scholar
  57. 57.
    Qi S, Xu D, Peng J, et al. (2000) Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono-and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation 69:1275–1283CrossRefPubMedGoogle Scholar
  58. 58.
    Reddy AR, Backhouse OC (2003) Does etanercept induce uveitis? Br J Ophthalmol 87:925CrossRefGoogle Scholar
  59. 59.
    Reiff A (2003) Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum 48:2079–2080CrossRefPubMedGoogle Scholar
  60. 60.
    Saenz A, Ausejo M, Shea B, et al. (2000) Pharmacotherapy for Behcet's syndrome. Cochrane Database Syst Rev 2Google Scholar
  61. 61.
    Saito H, Ebinuma H, Satoh I, et al. (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7:64–74CrossRefPubMedGoogle Scholar
  62. 62.
    Samson CM, Waheed N, Baltatzis S, et al. (2001) Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 108:1134–1139CrossRefPubMedGoogle Scholar
  63. 63.
    Saulsbury FT, Mann JA (2003) Treatment with infliximab for a child with Behcet's disease. Arthritis Rheum 49:599–600CrossRefPubMedGoogle Scholar
  64. 64.
    Sfikakis PP (2002) Behcet's disease: a new target for anti-tumour necrosis factor treatment. Ann Rheum Dis 61Suppl 2:ii51–53PubMedGoogle Scholar
  65. 65.
    Shah SS, Lowder CY, Schmitt MA, et al. (1992) Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 99:1419–1423PubMedGoogle Scholar
  66. 66.
    Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57:1885–1888PubMedGoogle Scholar
  67. 67.
    Silman AJ, Petrie J, Hazleman B, et al. (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 47:988–992PubMedGoogle Scholar
  68. 68.
    Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723–728CrossRefPubMedGoogle Scholar
  69. 69.
    Smith J-R (2002) Management of uveitis in pediatric patients: special considerations. Paediatr Drugs 4:183–189PubMedGoogle Scholar
  70. 70.
    Smith JA, Smith S, Whitcup SM, et al. (2002) The treatment of JRA-associated uveitis with etanercept. Arthritis Rheum 46:S482CrossRefGoogle Scholar
  71. 71.
    Stawell R (2003) Methotrexate in inflammatory eye disease. Ocul Immunol Inflamm 11:79–82CrossRefPubMedGoogle Scholar
  72. 72.
    Stockman GD, Heim LR, South MA, et al. (1973) Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol 110:277–282PubMedGoogle Scholar
  73. 73.
    Taniguchi M, Harada M, Kojo S, et al. (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21:483–513CrossRefPubMedGoogle Scholar
  74. 74.
    ten Tusscher MP, Jacobs PJ, Busch MJ, et al. (2003) Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 326:579CrossRefPubMedGoogle Scholar
  75. 75.
    Thurau SR, Diedrichs-Möhring M, Fricke H, et al. (1999) Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. Immunol Lett 68:205–212CrossRefPubMedGoogle Scholar
  76. 76.
    Thurau SR, Wildner G (2003) An HLA-peptide mimics organ-specific antigen in autoimmune uveitis: its role in pathogenesis and therapeutic induction of oral tolerance. Autoimm Rev 2:171–176CrossRefGoogle Scholar
  77. 77.
    Tseng S, Pak G, Washenik K, et al. (1996) Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 35:969–979CrossRefPubMedGoogle Scholar
  78. 78.
    Uchio E, Matsumoto T, Tanaka SI, et al. (1999) Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behcet's disease and Vogt-Koyanagi-Harada's disease. Clin Exp Rheumatol 17:179–184PubMedGoogle Scholar
  79. 79.
    Weiner HL (2001) Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes Infect 3:947–954CrossRefPubMedGoogle Scholar
  80. 80.
    Wildner G, Thurau SR (1994) Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide: a clue to major histocompatibility complex association with autoimmune disease. Eur J Immunol 24:2579–2585PubMedGoogle Scholar
  81. 81.
    Wilson SB, Kent SC, Patton KT, et al. (1998) Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 391:177–181CrossRefPubMedGoogle Scholar
  82. 82.
    Zierhut M, Stubiger N, Aboalchamat W, et al. (2001) Immunosuppressive therapy with mycophenolate mofetil (CellCept) in treatment of uveitis. Ophthalmologe 98:647–651CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Stephan R. Thurau
  • Gerhild Wildner

There are no affiliations available

Personalised recommendations